Literature DB >> 23001511

Evaluation of melanogenesis in A-375 melanoma cells treated with 5,7-dimethoxycoumarin and valproic acid.

Ewa Chodurek1, Arkadiusz Orchel, Joanna Orchel, Sławomir Kurkiewicz, Natalia Gawlik, Zofia Dzierżewicz, Krystyna Stępień.   

Abstract

Malignant melanoma (melanoma malignum) is one of the most dangerous types of tumor. It is very difficult to cure. In recent years, a lot of attention has been given to chemoprevention. This method uses natural and synthetic compounds to interfere with and inhibit the process of carcinogenesis. In this study, a new treatment strategy was proposed consisting of a combination of 5,7-dimethoxycoumarin (DMC), an activator of melanogenesis, and valproic acid (VPA), a well-known drug that is one of the histone deacetylase inhibitors (HDACis). In conjunction with 1 mM VPA, all of the tested concentrations of DMC (10-150 μM) significantly decreased the proliferation of A-375 cells. VPA and DMC also induced the synthesis of melanin and the formation of dendrite and star-shaped cells. Tyrosinase gene expression and tyrosinase activity significantly increased in response to VPA treatment. Pyrolysis with gas chromatography and mass spectrometry (Py-GC/MS) was used to investigate the structure of the isolated melanin. This showed that the quantitative and qualitative components of melanin degradation products are dependent on the type of applied melanogenesis inductor. Products derived from eumelanin were detected in the pyrolytic profile of melanin isolated from A-375 cells stimulated with DMC. Thermal degradation of melanin isolated from melanoma cells after exposure to VPA or a mixture of VPA and DMC revealed the additional presence of products derived from pheomelanin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23001511      PMCID: PMC6275710          DOI: 10.2478/s11658-012-0033-4

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  49 in total

1.  Proliferation and cellular death of A375 cell line in the presence of HDACs inhibitors.

Authors:  Ewa Chodurek; Arkadiusz Orchel; Natalia Gawlik; Anna Kulczycka; Arkadiusz Gruchlik; Zofia Dzierzewicz
Journal:  Acta Pol Pharm       Date:  2010 Nov-Dec       Impact factor: 0.330

2.  5-S-cysteinyldopa as diagnostic tumor marker for uveal malignant melanoma.

Authors:  H Goto; M Usui; K Wakamatsu; S Ito
Journal:  Jpn J Ophthalmol       Date:  2001 Sep-Oct       Impact factor: 2.447

Review 3.  Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer.

Authors:  Aoife Lacy; Richard O'Kennedy
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

4.  Cell cycle arrest and differentiation induction by 5,7-dimethoxycoumarin in melanoma cell lines.

Authors:  Daniela Alesiani; Rosella Cicconi; Maurizio Mattei; Carla Montesano; Roberto Bei; Antonella Canini
Journal:  Int J Oncol       Date:  2008-02       Impact factor: 5.650

Review 5.  Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.

Authors:  Shuyang Chen; Nianli Sang
Journal:  J Biomed Biotechnol       Date:  2010-12-05

6.  GC/MS analysis of thermally degraded neuromelanin from the human substantia nigra.

Authors:  Anna Dzierzega-Lecznar; Slawomir Kurkiewicz; Krystyna Stepien; Ewa Chodurek; Tadeusz Wilczok; Thomas Arzberger; Peter Riederer; Manfred Gerlach
Journal:  J Am Soc Mass Spectrom       Date:  2004-06       Impact factor: 3.109

7.  Inhibition of Mek 1/2 kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells.

Authors:  Daniela Alesiani; Rosella Cicconi; Maurizio Mattei; Roberto Bei; Antonella Canini
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

8.  Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.

Authors:  Adil I Daud; Jana Dawson; Ronald C DeConti; Elona Bicaku; Douglas Marchion; Sem Bastien; Frederick A Hausheer; Richard Lush; Anthony Neuger; Daniel M Sullivan; Pamela N Munster
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

9.  GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes.

Authors:  Barbara Bellei; Enrica Flori; Enzo Izzo; Vittoria Maresca; Mauro Picardo
Journal:  Cell Signal       Date:  2008-06-12       Impact factor: 4.315

Review 10.  Treatment of metastatic melanoma: an overview.

Authors:  Shailender Bhatia; Scott S Tykodi; John A Thompson
Journal:  Oncology (Williston Park)       Date:  2009-05       Impact factor: 2.990

View more
  4 in total

1.  Valproic acid causes proteasomal degradation of DICER and influences miRNA expression.

Authors:  Zhaiyi Zhang; Paolo Convertini; Manli Shen; Xiu Xu; Frédéric Lemoine; Pierre de la Grange; Douglas A Andres; Stefan Stamm
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

Review 2.  Upregulation of Melanogenesis and Tyrosinase Activity: Potential Agents for Vitiligo.

Authors:  Chao Niu; Haji A Aisa
Journal:  Molecules       Date:  2017-08-04       Impact factor: 4.411

Review 3.  From Extraction to Advanced Analytical Methods: The Challenges of Melanin Analysis.

Authors:  Ioana-Ecaterina Pralea; Radu-Cristian Moldovan; Alina-Maria Petrache; Maria Ilieș; Simona-Codruța Hegheș; Irina Ielciu; Raul Nicoară; Mirela Moldovan; Mihaela Ene; Mihai Radu; Alina Uifălean; Cristina-Adela Iuga
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

4.  Preparation of novel 1,2,3-triazole furocoumarin derivatives via click chemistry and their anti-vitiligo activity.

Authors:  Chao Niu; Xueying Lu; Haji Akber Aisa
Journal:  RSC Adv       Date:  2019-01-14       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.